The first phase of Project RED was supported by grant number 1 U18 HS015905-01 from the Agency for Healthcare Research and Quality (AHRQ). The creation of the Re Engineered Discharge was funded by AHRQ by grant number 1 UC1 HS14289-01 between September 2003 and September of 2004. The Virtual Patient Advocate to Reduce Ambulatory Adverse Drug Events project that is currently in its design phase is being funded by AHRQ grant number R18HSO17196-01.
The Agency for Healthcare Research and Quality (AHRQ) is the lead Federal agency charged with improving the quality, safety, efficiency, and effectiveness of health care for all Americans. As one of 12 agencies within the Department of Health and Human Services, AHRQ supports health services research that will improve the quality of health care and promote evidence-based decision making.
The second phase of Project RED was supported by grant number R01 HL081307 from the National Institutes of Health: National Heart, Lung and Blood Institute (NHLBI).
National Heart, Lung and Blood Institute (NHLBI) is part of the NIH and enables research about prevention, diagnosis and treatment of blood, heart, lung and sleep disorders.
The contents of this product are solely the responsibility of Brian Jack, MD and Boston Medical Center and do not necessarily represent the official view of or imply endorsement by AHRQ, the U.S. Department of Health and Human Services, NHLBI or the National Institutes of Health.